The main obstacles to successful hematopoietic stem cell transplantation for patients with chronic myeloid leukemia (CML) in blast crisis (BC) are increased posttransplant relapse and high treatment-related mortality. We report a patient with CML in BC who was treated initially with imatinib mesylate and was then concurrently treated with a nonmyeloablative stem cell transplant. Successful engraftment of donor cells followed by complete cytogenetic remission was achieved in the absence of severe therapy-related toxicities. This case demonstrates that imatinib mesylate given through nonmyeloablative transplant is a minimally toxic therapeutic approach, which does not compromise engraftment and may result in a favorable outcome in patients with CML in BC.
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The natural history of chronic myeloid leukemia (CML) is a progression from a benign chronic phase to a rapidly fatal blast crisis (BC) within 3-5 years. 1 Once the disease progresses into BC, there is no proven standard therapy and the prognosis for these patients is poor. 2, 3 Multiagent chemotherapy induces responses in only about 20% of patients with myeloblastic transformation and 50% of those with lymphoblastic transformation. 2, 4 The median survival is 2-6 months and 9-12 months for nonlymphoid and lymphoid blastic phases respectively. 2, 4 Allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative conditioning may be attempted, but this modality is associated with very poor survival as a result of high rates of both post-transplant relapse and nonrelapse mortality. 3, 5 Imatinib mesylate (STI 571; Glivec; Gleevec) monotherapy for CML in BC is valuable in the short term, but does not appear to have any influence on the long-term clinical outcome. 3, 6, 7 Since the outcome of HSCT may be better in patients with BC transplanted in second chronic phase, 8 the activity of imatinib mesylate in patients with BC suggests that it may be a useful bridge to transplantation. The use of a nonmyeloablative regimen may afford advantages by avoiding undesirable transplant-related toxicities and, potentially, nonrelapse mortality.
We report of a patient with CML in BC who was treated with imatinib mesylate. Imatinib mesylate was subsequently given throughout the nonmyeloablative preparatory regimen, and HSCT from his HLA identical sibling.
Case report
A 21-year-old Chinese man was diagnosed with Philadephia (Ph)-chromosome-positive CML in chronic phase in November 2000. He declined human leukocyte antigen (HLA)-identical sibling allogeneic HSCT on the basis of the transplant-related mortality and morbidity, and opted to receive treatment with a-interferon in combination with low-doses subcutaneous cytarabine arabinoside. The disease remained refractory to therapy despite escalating doses of interferon and cytarabine arabinoside. In October 2001, 11 months after the initial diagnosis, the disease progressed into the blastic phase. Full blood count showed a white blood cell count of 17.8 Â 10 9 /l, hemoglobin of 12.3 g/dl and platelet count of 40 Â 10 9 /l with peripheral blasts of 10%. Bone marrow examination showed 56% myeloid blasts. Cytogenetic evaluation revealed only the Ph chromosome without any additional cytogenetic abnormality.
He was started on imatinib mesylate 600 mg p.o. daily in October 2001. The therapy was well tolerated. During the third week of therapy, he progressively developed grade 4 cytopenia (absolute neutrophil count o0.5 Â 10 9 /l; platelet count o10 Â 10 9 /l) and imatinib mesylate was initially reduced to 300 mg daily. Bone marrow aspiration and trephine biopsy revealed severe hypoplasia with 3-5% blasts. Cytogenetic evaluation showed persistence of the Ph chromosome. Imatinib mesylate was increased back to 400 mg daily and the patient continued to require platelet transfusion once a week.
As the patient was still adverse to the toxicities of myeloablative transplantation, we opted to proceed with a nonmyeloablative approach. Given the likelihood that the rapid proliferation of leukemia cells in BC could outpace the graft-versus-leukemia (GVL) effects of the allograft, we decided to continue giving imatinib mesylate throughout the nonmyeloablative transplant. This approach has been approved by the Ethics Committee of our institution and informed consent from the patient was obtained.
Granulocyte-colony-stimulating factor (GCSF) mobilized peripheral blood stem cell (PBSC) from his HLA-identical sibling with a cell dose of 5.5 Â 10 6 /kg. CD34 positive cells were infused following conditioning with fludarabine 30 mg/m 2 daily for 3 days (day -4 to day -2) and total body irradiation (TBI) 200 cGy on day 0. Graft-versus-host disease (GVHD) prophylaxis comprised oral cyclosporin-A (CSA) 3 mg/kg twice daily from day 1, oral mycophenolate mofetil (MMF) 15 mg/kg twice daily from day 0 of transplant, and intravenous methotrexate 10 mg/m 2 on days 1, 3, 6 and 11 post-transplant. Prophylatic antimicrobials comprised oral ciprofloxacin 500 mg twice daily and oral fluconazole 200 mg once daily. Upon neutrophil engraftment, he was also given oral trimethoprim-sulfamethoxazole 80 mg/400 mg two tablets twice a day on weekends as prophylaxis against Pneumocystis carinii.
He tolerated the conditioning well. At 3 days after the stem cell infusion, he developed grade 4 neutropenia, which persisted until day 11 when the decision to initiate GCSF was made. He remained platelet transfusion dependent. He developed grade 2-3 nausea and vomiting from day 18 and was presumptively treated for GVHD of the stomach with prednisolone 1 mg/kg. When the symptoms worsened on day 28 with an associated skin rash, the steroid dose was increased to 2 mg/kg daily, with subsequent resolution of his symptoms. His performance status remained unchanged at 90% on the Karnofsky score.
Neutrophil and platelet engraftment were achieved on days 15 and 17, respectively (Figure 1 ). Bone marrow aspiration done on day 28 showed no blast cells. Reverse transcriptase polymerase chain reaction (RT-PCR) for the Bcr-Abl transcript was still positive post-transplant, but cytogenetic assessment showed complete cytogenetic remission and FISH analysis showed o1% BCR-ABL-positive nuclei, equivalent to the threshold of detection. Donor chimerism levels in peripheral blood showed 75-87.5% donor cells on days 14 and 28 post-transplant. At the time of reporting, this had increased to 95% on day 54 posttransplant. His symptoms of nausea resolved with predisolone therapy and the dose was gradually tapered. He is now in his ninth month post-transplant and remains in cytogenetic remission.
Discussion
The main obstacles to successful allogeneic HSCT in CML in BC are increased post-transplant relapse rates and a high treatment-related mortality, especially with myeloablative conditioning regimens. 3, 5 Nevertheless, allogeneic HSCT should be considered if there is a suitable donor, as there is a small but significant curative potential. 9 Imatinib mesylate has been shown in two phase II trials to have substantial clinical activity with a favorable safety profile when used as a single agent in patients with CML in BC. 6, 7 However, the short median survival of 6 and 8 months in these patients is similar to those treated before the era of imatinib mesylate. Owing to its acceptable toxicity profile and impressive efficacy in inducing hematological control, imatinib mesylate has been proposed as an adjunct to allogeneic HSCT. 6 CML has been the disease in which a GVL effect is best documented. 10 Nonmyeloablative HSCT, by harnessing the therapeutic benefit of immune-mediated GVL effect, has the potential to cure this disease without the toxicities of a myeloablative regimen. 11 However, the use of nonmyeloablative transplantation has generally been unsuccessful in patients with active aggressive malignancies. 12 CML in BC, as in any other refractory acute leukemia, may recur rapidly after a nonmyeloablative regimen and outpace the generation of graft-versusmalignancy effects. Previous studies have shown that pretransplantation therapy leading to a return from BC to chronic phase is associated with a greatly improved transplant outcome. 8 However, this usually involves the use of combination chemotherapy that is associated with significant morbidity and may render the patient a poor candidate for transplantation. Therefore, a less toxic therapeutic approach to achieve this goal is warranted. The use of imatinib mesylate may potentially allow disease control before transplantation and the full development of the donor immune system.
However, when such an approach is employed, imatinib mesylate is traditionally stopped just prior to the transplant. The discontinuation of imatinib mesylate pretransplant is for several reasons. Firstly, as imatinib mesylate may cause some suppression of normal hematopoeisis via its inhibitory effect on colony formation, 13, 14 there has been controversy about whether imatinib given during HSCT will cause suppression of donor stem cells and therefore result in graft failure. However, Chambon-Pautas et al 15 demonstrated in their small series of patients with Phchromosome-positive leukemias that imatinib mesylate treatment prior to SCT did not compromise engraftment and the uneventful donor hematopoietic reconstitution in that study illustrates the feasibility of such an approach.
Secondly, the safety of imatinib mesylate when given concommitantly with the multiple drugs for HSCT is unknown. Since the drug is predominatly metabolized in the liver by the CYP3A4/5 P-450 enzyme system, several groups of drugs commonly used during HSCT, such as the azoles and antibiotics, might be expected to increase the level of imatinib mesylate. 16 Drugs metabolized by this enzyme system may compete with imatinib mesylate for metabolism, potentially leading to increased levels of both drugs. In particular, increased levels of cyclosporin have been observed in post-transplant patients treated with imatinib. 16 Nevertheless, with close monitoring of cyclosporin levels and other evidence of drug-induced toxicities, such hurdles can be overcome.
In this report, we have demonstrated that after bringing a patient with CML in BC under control with imatinib mesylate, it was possible to continue the drug throughout HSCT in the absence of severe therapy-related toxicities, and with the attainment of complete cytogenetic remission and robust donor engraftment by the fourth week posttransplant. For patients who are unfit or unwilling to undergo a myeloablative transplant, this strategy is indeed a useful alternative.
Several issues remain unresolved with regard to the combination of imatinib mesylate and nonmyeloablative HSCT for CML in BC: When is the optimum time to discontinue imatinib mesylate should the patient achieve molecular remission? If the disease relapses upon discontinuation of imatinib mesylate, should the first-line therapy be donor lymphocyte infusion, reinitiation of imatinib mesylate, or both? Longer follow-up and further studies are warranted to confirm this preliminary result. This new strategy has potential important implications in the treatment of this fatal malignant disease. The future challenge will be to develop strategies to optimize the chance of early and durable engraftment, as well as to minimize the risk of GHVD and relapse.
